1
|
Badamasi IM, Tajudeen A, Owolabi SD, Ojeahere MI, Yusuf AA, Sirajo MU, Gudaji MI. Waist-height ratio highlights detrimental risk for olanzapine associated weight gain earlier than body mass index. Int J Adolesc Med Health 2024:ijamh-2024-0099. [PMID: 39432346 DOI: 10.1515/ijamh-2024-0099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2024] [Accepted: 10/03/2024] [Indexed: 10/22/2024]
Abstract
OBJECTIVE The objective of the current study was to compare the level of sensitivity of body mass index (BMI) or waist-height ratio (WHtR) in identifying physically determinable adiposity levels that are considered to be landmarks for commencing intervention to prevent more sinister cardio-metabolic risks among schizophrenia patients receiving olanzapine. METHODS The study was a descriptive crossectional one among patients with schizophrenia recieving olanzapine and healthy volunteers as controls. Key measurement of anthropological parameters were compared between the population. RESULTS Our findings revealed significantly higher rates of abnormal body mass index (BMI) (X2=17.06, p=0.000036; OR=4.58, CI=2.16-9.74) and abnormal waist-height ratio (WHtR) (X2=35.57, p=2.46E-9; OR=6.37, CI=3.39-12.00) among the schizophrenia patients compared to the healthy volunteers. Notably, BMI identified 43.3 % of the schizophrenia patients as having concerning weight changes, whereas WHtR identified 64.7 %, indicating that WHtR is a more sensitive measure. This discrepancy means that an additional 21.4 % of schizophrenia patients would benefit from weight management guidance based on WHtR rather than BMI. CONCLUSION Our results underscore the critical importance of WHtR in assessing adiposity among schizophrenia patients treated with olanzapine, highlighting its value as a tool for monitoring and managing cardiometabolic risks in this population.
Collapse
Affiliation(s)
- Ibrahim Mohammed Badamasi
- Department of Anatomy, Pharmacogenomics and Pharmacometabolomics Unit, Faculty of Basic Medical Sciences, College of Health Sciences, Bayero University Kano, Kano, Nigeria
- Formerly of the Pharmacotherapeutics Unit, Department of Medicine, Faculty of Medicine and Health Sciences, 37449 Universiti Putra Malaysia , Serdang, Selangor, Malaysia
| | - Abiola Tajudeen
- Federal Neuropsychiatry Hospital, Barnawa Kaduna State Nigeria, Kaduna, Nigeria
| | | | | | - Asuku A Yusuf
- Department of Anatomy, Pharmacogenomics and Pharmacometabolomics Unit, Faculty of Basic Medical Sciences, College of Health Sciences, Bayero University Kano, Kano, Nigeria
- Formerly of the Pharmacotherapeutics Unit, Department of Medicine, Faculty of Medicine and Health Sciences, 37449 Universiti Putra Malaysia , Serdang, Selangor, Malaysia
| | | | | |
Collapse
|
2
|
Perna G, Spiti A, Torti T, Daccò S, Caldirola D. Biomarker-Guided Tailored Therapy in Major Depression. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2024; 1456:379-400. [PMID: 39261439 DOI: 10.1007/978-981-97-4402-2_19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/13/2024]
Abstract
This chapter provides a comprehensive examination of a broad range of biomarkers used for the diagnosis and prediction of treatment outcomes in major depressive disorder (MDD). Genetic, epigenetic, serum, cerebrospinal fluid (CSF), and neuroimaging biomarkers are analyzed in depth, as well as the integration of new technologies such as digital phenotyping and machine learning. The intricate interplay between biological and psychological elements is emphasized as essential for tailoring MDD management strategies. In addition, the evolving link between psychotherapy and biomarkers is explored to uncover potential associations that shed light on treatment response. This analysis underscores the importance of individualized approaches in the treatment of MDD that integrate advanced biological insights into clinical practice to improve patient outcomes.
Collapse
Affiliation(s)
- Giampaolo Perna
- Department of Biomedical Sciences, Humanitas University, Milan, Italy.
- Department of Clinical Neurosciences, Hermanas Hospitalarias, Villa San Benedetto Menni Hospital, Como, Italy.
- Humanitas SanpioX, Milan, Italy.
| | - Alessandro Spiti
- IRCCS Humanitas Research Hospital, Milan, Italy
- Psicocare, Humanitas Medical Care, Monza, Italy
| | - Tatiana Torti
- ASIPSE School of Cognitive-Behavioral-Therapy, Milan, Italy
| | - Silvia Daccò
- Department of Biomedical Sciences, Humanitas University, Milan, Italy
- Humanitas SanpioX, Milan, Italy
- Psicocare, Humanitas Medical Care, Monza, Italy
| | - Daniela Caldirola
- Department of Biomedical Sciences, Humanitas University, Milan, Italy
- Department of Clinical Neurosciences, Hermanas Hospitalarias, Villa San Benedetto Menni Hospital, Como, Italy
- Humanitas SanpioX, Milan, Italy
| |
Collapse
|
3
|
Sandritter T, Chevalier R, Abt R, Shakhnovich V. Pharmacogenetic Testing for the Pediatric Gastroenterologist: Actionable Drug-Gene Pairs to Know. Pharmaceuticals (Basel) 2023; 16:889. [PMID: 37375836 DOI: 10.3390/ph16060889] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2023] [Revised: 06/09/2023] [Accepted: 06/13/2023] [Indexed: 06/29/2023] Open
Abstract
Gastroenterologists represent some of the earlier adopters of precision medicine through pharmacogenetic testing by embracing upfront genotyping for thiopurine S-methyltransferase nucleotide diphosphatase (TPMT) before prescribing 6-mercaptopurine or azathioprine for the treatment of inflammatory bowel disease. Over the last two decades, pharmacogenetic testing has become more readily available for other genes relevant to drug dose individualization. Common medications prescribed by gastroenterologists for conditions other than inflammatory bowel disease now have actionable guidelines, which can improve medication efficacy and safety; however, a clear understanding of how to interpret the results remains a challenge for many clinicians, precluding wide implementation of genotype-guided dosing for drugs other than 6-mercaptopurine and azathioprine. Our goal is to provide a practical tutorial on the currently available pharmacogenetic testing options and a results interpretation for drug-gene pairs important to medications commonly used in pediatric gastroenterology. We focus on evidence-based clinical guidelines published by the Clinical Pharmacogenetics Implementation Consortium (CPIC®) to highlight relevant drug-gene pairs, including proton pump inhibitors and selective serotonin reuptake inhibitors and cytochrome P450 (CYP) 2C19, ondansetron and CYP2D6, 6-mercaptopurine and TMPT and Nudix hydrolase 15 (NUDT15), and budesonide and tacrolimus and CYP3A5.
Collapse
Affiliation(s)
- Tracy Sandritter
- Division of Clinical Pharmacology/Medical Toxicology and Therapeutic Innovation, Children's Mercy Hospital, 2401 Gillham Road, Kansas City, MO 64108, USA
- Department of Pharmacy Practice, School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO 64108, USA
| | - Rachel Chevalier
- Division of Gastroenterology, Children's Mercy Hospital, 2401 Gillham Rd., Kansas City, MO 64108, USA
- Department of Pediatrics, School of Medicine, University of Missouri-Kansas City, Kansas City, MO 64108, USA
| | - Rebecca Abt
- ProPharma Group, Overland Park, KS 66210, USA
| | - Valentina Shakhnovich
- Division of Clinical Pharmacology/Medical Toxicology and Therapeutic Innovation, Children's Mercy Hospital, 2401 Gillham Road, Kansas City, MO 64108, USA
- Department of Pediatrics, School of Medicine, University of Missouri-Kansas City, Kansas City, MO 64108, USA
| |
Collapse
|
4
|
Insights into the Promising Prospect of G Protein and GPCR-Mediated Signaling in Neuropathophysiology and Its Therapeutic Regulation. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY 2022; 2022:8425640. [PMID: 36187336 PMCID: PMC9519337 DOI: 10.1155/2022/8425640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/23/2022] [Accepted: 08/23/2022] [Indexed: 11/18/2022]
Abstract
G protein-coupled receptors (GPCRs) are intricately involved in the conversion of extracellular feedback to intracellular responses. These specialized receptors possess a crucial role in neurological and psychiatric disorders. Most nonsensory GPCRs are active in almost 90% of complex brain functions. At the time of receptor phosphorylation, a GPCR pathway is essentially activated through a G protein signaling mechanism via a G protein-coupled receptor kinase (GRK). Dopamine, an important neurotransmitter, is primarily involved in the pathophysiology of several CNS disorders; for instance, bipolar disorder, schizophrenia, Parkinson's disease, and ADHD. Since dopamine, acetylcholine, and glutamate are potent neuropharmacological targets, dopamine itself has potential therapeutic effects in several CNS disorders. GPCRs essentially regulate brain functions by modulating downstream signaling pathways. GPR6, GPR52, and GPR8 are termed orphan GPCRs because they colocalize with dopamine D1 and D2 receptors in neurons of the basal ganglia, either alone or with both receptors. Among the orphan GPCRs, the GPR52 is recognized for being an effective psychiatric receptor. Various antipsychotics like aripiprazole and quetiapine mainly target GPCRs to exert their actions. One of the most important parts of signal transduction is the regulation of G protein signaling (RGS). These substances inhibit the activation of the G protein that initiates GPCR signaling. Developing a combination of RGS inhibitors with GPCR agonists may prove to have promising therapeutic potential. Indeed, several recent studies have suggested that GPCRs represent potentially valuable therapeutic targets for various psychiatric disorders. Molecular biology and genetically modified animal model studies recommend that these enriched GPCRs may also act as potential therapeutic psychoreceptors. Neurotransmitter and neuropeptide GPCR malfunction in the frontal cortex and limbic-related regions, including the hippocampus, hypothalamus, and brainstem, is likely responsible for the complex clinical picture that includes cognitive, perceptual, emotional, and motor symptoms. G protein and GPCR-mediated signaling play a critical role in developing new treatment options for mental health issues, and this study is aimed at offering a thorough picture of that involvement. For patients who are resistant to current therapies, the development of new drugs that target GPCR signaling cascades remains an interesting possibility. These discoveries might serve as a fresh foundation for the creation of creative methods for pharmacologically useful modulation of GPCR function.
Collapse
|
5
|
Li LD, Naveed M, Du ZW, Ding H, Gu K, Wei LL, Zhou YP, Meng F, Wang C, Han F, Zhou QG, Zhang J. Abnormal expression profile of plasma-derived exosomal microRNAs in patients with treatment-resistant depression. Hum Genomics 2021; 15:55. [PMID: 34419170 PMCID: PMC8379796 DOI: 10.1186/s40246-021-00354-z] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2021] [Accepted: 08/02/2021] [Indexed: 02/07/2023] Open
Abstract
Whether microRNAs (miRNAs) from plasma exosomes might be dysregulated in patients with depression, especially treatment-resistant depression (TRD), remains unclear, based on study of which novel biomarkers and therapeutic targets could be discovered. To this end, a small sample study was performed by isolation of plasma exosomes from patients with TRD diagnosed by Hamilton scale. In this study, 4 peripheral plasma samples from patients with TRD and 4 healthy controls were collected for extraction of plasma exosomes. Exosomal miRNAs were analyzed by miRNA sequencing, followed by image collection, expression difference analysis, target gene GO enrichment analysis, and KEGG pathway enrichment analysis. Compared with the healthy controls, 2 miRNAs in the plasma exosomes of patients with TRD showed significant differences in expression, among which has-miR-335-5p were significantly upregulated and has-miR-1292-3p were significantly downregulated. Go and KEGG analysis showed that dysregulated miRNAs affect postsynaptic density and axonogenesis as well as the signaling pathway of axon formation and cell growths. The identification of these miRNAs and their target genes may provide novel biomarkers for improving diagnosis accuracy and treatment effectiveness of TRD.
Collapse
Affiliation(s)
- Lian-Di Li
- Department of Clinical Pharmacology, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, Jiangsu Province, China
| | - Muhammad Naveed
- Department of Clinical Pharmacology, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, Jiangsu Province, China
| | - Zi-Wei Du
- Department of Clinical Pharmacology, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, Jiangsu Province, China
| | - Huachen Ding
- Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, 210029, Jiangsu Province, China.,Functional Brain Imaging Institute of Nanjing Medical University, Nanjing, 210029, Jiangsu Province, China
| | - Kai Gu
- Sir Run Run Hospital, Nanjing Medical University, Nanjing, 211167, Jiangsu Province, China
| | - Lu-Lu Wei
- Department of Clinical Pharmacology, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, Jiangsu Province, China
| | - Ya-Ping Zhou
- Department of Clinical Pharmacology, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, Jiangsu Province, China
| | - Fan Meng
- Department of Clinical Pharmacology, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, Jiangsu Province, China
| | - Chun Wang
- Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, 210029, Jiangsu Province, China.,Functional Brain Imaging Institute of Nanjing Medical University, Nanjing, 210029, Jiangsu Province, China
| | - Feng Han
- Key Laboratory of Cardiovascular and Cerebrovascular Medicine, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, Jiangsu Province, China.
| | - Qi-Gang Zhou
- Department of Clinical Pharmacology, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, Jiangsu Province, China. .,Sir Run Run Hospital, Nanjing Medical University, Nanjing, 211167, Jiangsu Province, China.
| | - Jing Zhang
- Department of Clinical Pharmacology, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, Jiangsu Province, China.
| |
Collapse
|